KCR

📚Precision medicine is shaping the future of #healthcare. By leveraging individual genetic profiles alongside lifestyle and environmental factors, we’re entering an era of personalized care - offering patients more accurate diagnoses, better outcomes, and fewer adverse effects. One powerful reminder from the article: “It is not a question of the kind of disease the patient has, but rather the kind of patient the disease has attacked.” – Professor Andrew R Robinson (1894) From cancer treatment breakthroughs to the evolving field of pharmacogenomics, the science is there. Now we must ensure healthcare systems, digital infrastructure, and policies catch up. 🧬 Read more from Anna Guildford about how genomic data is revolutionizing medicine - and why collaboration, education, and public trust are key to making it standard care.👇 https://lnkd.in/eTT4wdmU

#KCRscienceRead Scientists at Cancer Research UK’s Manchester Institute have developed a lab-grown model of lung squamous cell carcinoma (LUSC) using CRISPR gene editing. This innovation could lead to more targeted treatments, better early detection, and reduce reliance on animal testing. “Lab-grown lung cancer cells show potential to revolutionise treatment. The model could lead to more targeted treatments for the disease.” This model marks a significant step forward in understanding LUSC, one of the least understood yet most common forms of lung cancer. 🔗 Read more: https://lnkd.in/eKTdbjgG #CancerResearch #LungCancer #CRISPR #Oncology #CRO #LifeSciences #Innovation

This year’s #WorldHealthDay, we stand with the global health community in supporting "Healthy beginnings, hopeful futures" - a call to prioritize maternal and newborn health. As a trusted CRO partner, we are committed to advancing clinical research that addresses and supports long-term health for women and families. With over 300,000 maternal deaths and 2 million newborn deaths annually, urgent action is essential. Learn more about how the science world is supporting global health initiatives👇 https://lnkd.in/d8nVsj82

Interesting read for today's #KCRScienceRead about Top ClinTech Predictions 2025. The article has been co-authored by KCR's Doug Bain, and sheds some light on digital transformation in the clinical research space. Read more about AI adoption, hybrid decentralised trial models and unified platforms in the #clinicaltrials. Full article here: https://lnkd.in/gYE2MGqQ

#KCRScienceRead Drug for rare form of Alzheimer’s “scientifically promising,” the recent research shows. In today's #KCRScienceRead we would like to highlight recent findings (for the first time in a clinical trials) indicating "that early removal of amyloid plaques in the brain years before symptoms are observed, may delay onset of Alzheimer’s dementia."  "Researchers investigated the effects of the experimental anti-amyloid drug gantenerumab to determine whether it could prevent participants developing dementia. The data offers new evidence supporting the amyloid hypothesis of Alzheimer’s." Read more in the News from European Pharmaceutical Review: https://lnkd.in/dkc5bCnf #Alzhaimer, #clinicalresearch, #KCRCRO

What's going on in the world of #Biosimilars? KCR Principal Consultant, Dr. Dave Li, and KCR Chief Medical Officer, Dr. Anna Baran, published a #whitepaper to tell you! The article, "The Imperfect Art of Biosimilars” works to dissect interchangeability for biosimilars and offers operational perspectives for consideration in the design and execution of clinical studies on biosimilars. Check it out!

🩺#AreYourKidneysOK? On #WorldKidneyDay, we encourage you to learn more about your kidney health - because these vital organs work tirelessly to keep you healthy. But how well do you know their condition? Take our quick kidney health quiz and find out if your kidneys are in good shape! Simply follow the link below.👇 https://lnkd.in/eF-sguYb

#PatientSafetyAwarenessWeek highlights the importance of healthcare safety and the collective efforts to enhance patient well-being. It encourages healthcare professionals, organizations, and patients to engage in discussions and initiatives that promote best practices, reduce errors, and improve communication. By fostering a culture of safety, we can ensure more effective and reliable care for all.

#KCRScienceRead The SECuRE trial has moved into Phase 2 (cohort expansion) after demonstrating remarkable PSA reductions in pre-chemo participants! The Safety Review Committee has approved increasing dose levels (up to 8 GBq) and treatment cycles (up to 6). 🔬 Key Findings: ✅ 68% of participants saw PSA drops, even after just one dose of 67Cu-SAR-bisPSMA. ✅ Pre-chemo participants responded exceptionally well – nearly half experienced PSA reductions of 80% or more. ✅ One participant achieved a complete response after just two doses (12 GBq). ✅ Disease control was achieved in 92% of pre-chemo participants. Dr. Alan Taylor, Clarity’s Executive Chairperson, shared: “The SECuRE trial continues to generate extraordinary results, and we are thrilled to progress to phase 2.” With expanded enrollment and a new combination therapy approach, this trial is shaping the future of prostate cancer treatment! 📖 Read more here 👉 https://lnkd.in/dF9NrTx8 #ProstateCancer #ClinicalTrials #Oncology #MedicalResearch

🌍 March 4 is #WorldObesityDay – a crucial moment to recognize obesity as a complex, chronic disease and a key driver of other serious health conditions. 🚨 Obesity is a global public health crisis, fueling the rise of diabetes, heart disease, and cancer. Addressing it isn't just about weight—it’s about reducing the burden of chronic diseases worldwide. 💡 It's time for action. By raising awareness, advocating for better policies, and supporting those affected, we can make a real difference. 🔗 Learn more here: https://lnkd.in/eS38U52 #WorldObesityDay #PublicHealth #ChronicDisease